Skip to main content

Advertisement

SpringerLink
Log in

Increased SPHK1 expression is associated with poor prognosis in bladder cancer

  • Research Article
  • Published:
Tumor Biology

Abstract

Upregulation of sphingosine kinase 1 (SPHK1) protein has been reported to be associated with a poor prognosis in a variety of malignant tumors. However, the role of SPHK1 in bladder cancer (BC) has not been thoroughly elucidated. The purpose of this study was to assess SPHK1 expression and to explore its contribution to BC. Real-time quantitative reverse transcriptase–polymerase chain reaction (qRT-PCR) was conducted to detect SPHK1 mRNA expression in 37 pairs of fresh-frozen BC tissues and corresponding noncancerous tissues. Results showed that SPHK1 mRNA expression level in BC tissues was significantly higher than that in corresponding noncancerous tissues. To investigate the association between SPHK1 protein expression and clinicopathological characteristics of BC, immunohistochemistry (IHC) was performed in 153 archived paraffin-embedded BC samples. Interestingly, high SPHK1 expression was significantly associated with histologic grade (P = 0.045) and tumor stage (P < 0.001) of patients with BC. The Kaplan–Meier survival curve showed that patients with high SPHK1 expression had significantly reduced overall 5-year survival rates (P < 0.001). Multivariate Cox regression analysis further suggested that the increased expression of SPHK1 was an independent poor prognostic factor for this disease. In conclusion, our data offer the convincing evidence for the first time that the increased expression of SPHK1 may be involved in the pathogenesis and progression of BC. SPHK1 might be a potential marker to predict the prognosis in BC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212–36. doi:10.3322/caac.20121.

    Article  PubMed  Google Scholar 

  2. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet. 2009;374:239–49. doi:10.1016/S0140-6736(09)60491-8.

    Article  PubMed  CAS  Google Scholar 

  3. Pryor WA. Cigarette smoke radicals and the role of free radicals in chemical carcinogenicity. Environ Health Perspect. 1997;105:875–82.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  4. Franekova M, Halasova E, Bukovska E, Luptak J, Dobrota D. Gene polymorphisms in bladder cancer. Urol Oncol. 2008;26:1–8. doi:10.1016/j.urolonc.2006.10.011.

    Article  PubMed  CAS  Google Scholar 

  5. Maceyka M, Payne SG, Milstien S, Spiegel S. Sphingosine kinase, sphingosine-1-phosphate, and apoptosis. Biochim Biophys Acta. 2002;1585:193–201.

    Article  PubMed  CAS  Google Scholar 

  6. Liu H, Chakravarty D, Maceyka M, Milstien S, Spiegel S. Sphingosine kinases: a novel family of lipid kinases. Prog Nucleic Acid Res Mol Biol. 2002;71:493–511.

    Article  PubMed  CAS  Google Scholar 

  7. Olivera A, Spiegel S. Sphingosine kinase: a mediator of vital cellular functions. Prostaglandins Other Lipid Mediat. 2001;64:123–34.

    Article  PubMed  CAS  Google Scholar 

  8. Liu H, Sugiura M, Nava VE, Edsall LC, Kono K, Poulton S, et al. Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform. J Biol Chem. 2000;275:19513–20. doi:10.1074/jbc.M002759200.

    Article  PubMed  CAS  Google Scholar 

  9. Van Brocklyn JR, Jackson CA, Pearl DK, Kotur MS, Snyder PJ, Prior TW. Sphingosine kinase-1 expression correlates with poor survival of patients with glioblastoma multiforme: roles of sphingosine kinase isoforms in growth of glioblastoma cell lines. J Neuropathol Exp Neurol. 2005;64:695–705.

    Article  PubMed  Google Scholar 

  10. Kohno M, Momoi M, Oo ML, Paik JH, Lee YM, Venkataraman K, et al. Intracellular role for sphingosine kinase 1 in intestinal adenoma cell proliferation. Mol Cell Biol. 2006;26:7211–23.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  11. Le Scolan E, Pchejetski D, Banno Y, Denis N, Mayeux P, Vainchenker W, et al. Overexpression of sphingosine kinase 1 is an oncogenic event in erythroleukemic progression. Blood. 2005;106:1808–16. doi:10.1182/blood-2004-12-4832.

    Article  PubMed  CAS  Google Scholar 

  12. Akao Y, Banno Y, Nakagawa Y, Hasegawa N, Kim TJ, Murate T, et al. High expression of sphingosine kinase 1 and S1P receptors in chemotherapy-resistant prostate cancer PC3 cells and their camptothecin-induced up-regulation. Biochem Biophys Res Commun. 2006;342:1284–90.

    Article  PubMed  CAS  Google Scholar 

  13. Kawamori T, Osta W, Johnson KR, Pettus BJ, Bielawski J, Tanaka T, et al. Sphingosine kinase 1 is up-regulated in colon carcinogenesis. FASEB J. 2006;20:386–8. doi:10.1096/fj.05-4331fje.

    PubMed  CAS  Google Scholar 

  14. Guan H, Liu L, Cai J, Liu J, Ye C, Li M, et al. Sphingosine kinase 1 is overexpressed and promotes proliferation in human thyroid cancer. Mol Endocrinol. 2011;25:1858–66. doi:10.1210/me.2011-1048.

    Article  PubMed  CAS  Google Scholar 

  15. Pan J, Tao YF, Zhou Z, Cao BR, Wu SY, Zhang YL, et al. An novel role of sphingosine kinase-1 (SPHK1) in the invasion and metastasis of esophageal carcinoma. J Transl Med. 2011;9:157. doi:10.1186/1479-5876-9-157.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  16. Fuereder T, Hoeflmayer D, Jaeger-Lansky A, Rasin-Streden D, Strommer S, Fisker N, et al. Sphingosine kinase 1 is a relevant molecular target in gastric cancer. Anticancer Drugs. 2011;22:245–52.

    Article  PubMed  CAS  Google Scholar 

  17. Bao M, Chen Z, Xu Y, Zhao Y, Zha R, Huang S, et al. Sphingosine kinase 1 promotes tumour cell migration and invasion via the S1P/EDG1 axis in hepatocellular carcinoma. Liver Int. 2012;32:331–8. doi:10.1111/j.1478-3231.2011.02666.x.

    Article  PubMed  CAS  Google Scholar 

  18. Kalari S, Moolky N, Pendyala S, Berdyshev EV, Rolle C, Kanteti R, et al. Sphingosine kinase 1 is required for mesothelioma cell proliferation: role of histone acetylation. PLoS One. 2012;7:e45330. doi:10.1371/journal.pone.0045330.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  19. Du ZM, Hu CF, Shao Q, Huang MY, Kou CW, Zhu XF, et al. Upregulation of caveolin-1 and CD147 expression in nasopharyngeal carcinoma enhanced tumor cell migration and correlated with poor prognosis of the patients. Int J Cancer. 2009;125(8):1832–41. doi:10.1002/ijc.24531.

    Article  PubMed  CAS  Google Scholar 

  20. Kim WJ, Kim EJ, Kim SK, Kim YJ, Ha YS, Jeong P, et al. Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Mol Cancer. 2010;9:3. doi:10.1186/1476-4598-9-3.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  21. Kim YK, Kim WJ. Epigenetic markers as promising prognosticators for bladder cancer. Int J Urol. 2009;16:17–22. doi:10.1111/j.1442-2042.2008.02143.x.

    Article  PubMed  Google Scholar 

  22. Habuchi T, Marberger M, Droller MJ, Hemstreet 3rd GP, Grossman HB, Schalken JA, et al. Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology. 2005;66:64–74. doi:10.1016/j.urology.2005.08.065.

    Article  PubMed  Google Scholar 

  23. Dyrskjøt L, Zieger K, Real FX, Malats N, Carrato A, Hurst C, et al. Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study. Clin Cancer Res. 2007;13:3545–51. doi:10.1158/1078-0432.CCR-06-2940.

    Article  PubMed  CAS  Google Scholar 

  24. Takata R, Katagiri T, Kanehira M, Tsunoda T, Shuin T, Miki T, et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res. 2005;11:2625–36. doi:10.1158/1078-0432.CCR-04-1988.

    Article  PubMed  CAS  Google Scholar 

  25. Eschrich S, Yang I, Bloom G, Kwong KY, Boulware D, Cantor A, et al. Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol. 2005;23:3526–35. doi:10.1200/JCO.2005.00.695.

    Article  PubMed  CAS  Google Scholar 

  26. Kim WJ, Kim SK, Jeong P, Yun SJ, Cho IC, Kim IY, et al. A four-gene signature predicts disease progression in muscle invasive bladder cancer. Mol Med. 2011;17:478–85. doi:10.2119/molmed.2010.00274.

    PubMed Central  PubMed  CAS  Google Scholar 

  27. Liu G, Zheng H, Zhang Z, Wu Z, Xiong H, Li J, et al. Overexpression of sphingosine kinase 1 is associated with salivary gland carcinoma progression and might be a novel predictive marker for adjuvant therapy. BMC Cancer. 2010;10:495. doi:10.1186/1471-2407-10-495.

    Article  PubMed Central  PubMed  Google Scholar 

  28. Facchinetti MM, Gandini NA, Fermento ME, Sterin-Speziale NB, Ji Y, Patel V, et al. The expression of sphingosine kinase-1 in head and neck carcinoma. Cells Tissues Organs. 2010;192:314–24. doi:10.1159/000318173.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  29. Li W, Yu CP, Xia JT, Zhang L, Weng GX, Zheng HQ, et al. Sphingosine kinase 1 is associated with gastric cancer progression and poor survival of patients. Clin Cancer Res. 2009;15:1393–9. doi:10.1158/1078-0432.CCR-08-1158.

    Article  PubMed  CAS  Google Scholar 

  30. Li J, Guan HY, Gong LY, Song LB, Zhang N, Wu J, et al. Clinical significance of sphingosine kinase-1 expression in human astrocytomas progression and overall patient survival. Clin Cancer Res. 2008;14:6996–7003. doi:10.1158/1078-0432.CCR-08-0754.

    Article  PubMed  CAS  Google Scholar 

  31. Rosa R, Marciano R, Malapelle U, Formisano L, Nappi L, D’Amato C, et al. Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models. Clin Cancer Res. 2013;19:138–47. doi:10.1158/1078-0432.CCR-12-1050.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Urology, Southwest Hospital, The Third Military Medical University, No. 30, Gaotanyanzheng Street, Shapingba District, Chongqing, 40038, China

    Xiao-Dong Meng, Zhan-Song Zhou & Wen-Hao Shen

  2. Department of Urology, The Bethune International Peace Hospital, No. 398, Zhongshan West Road, Shijiazhuang, 050082, China

    Xiao-Dong Meng & Jian-Hong Qiu

  3. The Bethune International Peace Hospital, No. 398, Zhongshan West Road, Shijiazhuang, 050082, China

    Qu Wu

  4. Department of Anesthesiology, The Bethune International Peace Hospital, No. 398, Zhongshan West Road, Shijiazhuang, 050082, China

    Jun Xiao

Authors
  1. Xiao-Dong Meng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhan-Song Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jian-Hong Qiu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wen-Hao Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Qu Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jun Xiao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Zhan-Song Zhou or Jian-Hong Qiu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Meng, XD., Zhou, ZS., Qiu, JH. et al. Increased SPHK1 expression is associated with poor prognosis in bladder cancer. Tumor Biol. 35, 2075–2080 (2014). https://doi.org/10.1007/s13277-013-1275-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-013-1275-0

Keywords

Search

Navigation